DOCSLIB.ORG

Information to Accompany Patients Undergoing Nuclear Medicine Procedures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Information to Accompany Patients Undergoing Nuclear Medicine Procedures HSE Health & Safety Executive Information to accompany patients undergoing nuclear medicine procedures Prepared by the Royal Surrey County Hospital and the University of Surrey for the Health and Safety Executive 2006 RESEARCH REPORT 416 HSE Health & Safety Executive Information to accompany patients undergoing nuclear medicine procedures Claire Greaves1, Victoria Senior2, Julie Barnett2, Marie Clark2, Joanna Pope2 and Paul Hinton1 Royal Surrey County Hospital 1Medical Physics Department Royal Surrey County Hospital Guildford Surrey GU2 7XX University of Surrey 2Department of Psychology University of Surrey Guildford Surrey GU2 7XH The aim of this research was to investigate information on restricting the exposure to radiation from nuclear medicine patients following diagnostic and therapeutic procedures. It comprised an audit of current practice in UK departments and interviews and focus groups exploring the views and experiences of patients and professionals. The majority of departments provide verbal and/or written information on restricting contact with others, particularly pregnant women and children. Fewer departments give instructions about minimising contamination. On the whole, information provided complies with or, in the case if diagnostic procedures, goes beyond the restrictions specified in the Medical and Dental Guidance Notes. Information is rarely produced in formats for people with disabilities or people who do not have English as a first language. We identified a need to communicate more effectively with patients the rationale for restrictions and the consequences of non-adherence. We also identified a need to raise awareness of radiation protection issues and disseminate information more effectively with professionals outside of nuclear medicine departments. Ways in which both of these needs can be addressed are discussed. This report and the work it describes were funded by the Health and Safety Executive and the Department of Health. Its contents, including any opinions and/or conclusions expressed, are those of the author(s) alone and do not necessarily reflect HSE or DoH policy. HSE BOOKS © Crown copyright 2006 First published 2006 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise) without the prior written permission of the copyright owner. Applications for reproduction should be made in writing to: Licensing Division, Her Majesty's Stationery Office, St Clements House, 2-16 Colegate, Norwich NR3 1BQ or by e-mail to [email protected] ii ACKNOWLEDGEMENTS We would like to thank the staff in the Medical Physics Department at the Royal Surrey County Hospital and members of the Institute of Physics in Medicine (IPEM) Nuclear Medicine Special Interest Group (NMSIG) for their help in piloting the questionnaire. We would also like to thank staff in the Medical Physics and Nuclear Medicine Departments at the Royal Surrey County Hospital for their help with recruitment of patients and the patients who agreed to take part in the study. Finally, we would like to thank all the participants in the focus groups and the workshops. Their comments were extremely valuable. iii iv CONTENTS Acknowledgements ...................................................................................................................... iii Contents......................................................................................................................................... v EXECUTIVE SUMMARY........................................................................................................... 1 Aims of the research ........................................................................................................... 1 Components of the research................................................................................................ 1 Main findings ...................................................................................................................... 1 1. MAIN REPORT................................................................................................................ 3 1.1. Introduction ............................................................................................................. 3 1.2. Current Advice ........................................................................................................ 4 1.3. Communication And Restrictions ........................................................................... 5 1.4. Aims And Objectives .............................................................................................. 6 1.5. Format Of The Report ............................................................................................. 7 1.6. Methods ................................................................................................................... 8 1.7. Results ..................................................................................................................... 9 1.8. Overall Conclusions .............................................................................................. 14 1.9. References ............................................................................................................. 15 2. ANNEX 1: NATIONAL SURVEY OF RADIATION PROTECTION INFORMATION PROVIDED IN ORDER TO MINIMISE THE HAZARD FROM NUCLEAR MEDICINE PATIENTS................................................................................................. 17 2.1. Introduction ........................................................................................................... 17 2.2. Aims And Objectives ............................................................................................ 18 2.3. Definitions ............................................................................................................. 18 2.4. Method................................................................................................................... 19 2.5. Results ................................................................................................................... 20 2.6. Discussion ............................................................................................................. 37 2.7. Conclusions ........................................................................................................... 40 2.8. Practical Implications ............................................................................................ 41 2.9. References ............................................................................................................. 42 3. ANNEX 2: EVALUATION OF DIAGNOSTIC AND THERAPEUTIC PATIENT INFORMATION LEAFLETS ....................................................................................... 43 3.1. Summary ............................................................................................................... 43 3.2. Overview ............................................................................................................... 43 3.3. Aims And Objectives ............................................................................................ 43 3.4. Method................................................................................................................... 44 3.5. Results ................................................................................................................... 46 3.6. Discussion ............................................................................................................. 55 3.7. Practical Implications ............................................................................................ 57 3.8. References ............................................................................................................. 58 4. ANNEX 3: EXPERIENCES AND PERCEPTIONS OF PATIENTS UNDERGOING DIAGNOSTIC AND THERAPEUTIC NUCLEAR MEDICINE PROCEDURES ...... 59 4.1. Summary ............................................................................................................... 59 4.2. Aims And Objectives ............................................................................................ 59 4.3. Method................................................................................................................... 60 4.4. Results ................................................................................................................... 61 4.5. Practical Implications ............................................................................................ 70 4.6. References ............................................................................................................. 71 v 5. ANNEX 4: UNDERSTANDING AND ACTING ON RADIATION PROTECTION INFORMATION: THE PERSPECTIVE OF HEALTH CARE PROFESSIONALS ... 73 5.1. Summary ............................................................................................................... 73 5.2. Aims And Objectives: ........................................................................................... 74 5.3. Method................................................................................................................... 74 5.4. Procedure............................................................................................................... 75 5.5. Practical Implications ...........................................................................................
Load more

Recommended publications
  • Managing Terrorism Or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: a Comprehensive Review
    Int. J. Environ. Res. Public Health 2014, 11, 4158-4200; doi:10.3390/ijerph110404158 OPEN ACCESS International Journal of Environmental Research and Public Health ISSN 1660-4601 www.mdpi.com/journal/ijerph Review Managing Terrorism or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: A Comprehensive Review Eric R. Braverman 1,2,3, Kenneth Blum 1,2,*, Bernard Loeffke 2, Robert Baker 4, 5, Florian Kreuk 2, Samantha Peiling Yang 6 and James R. Hurley 7 1 Department of Psychiatry, College of Medicine, University of Florida and McKnight Brain Institute, Gainesville, FL 32610, USA; E-Mail: [email protected] 2 Department of Clinical Neurology, PATH Foundation NY, New York, NY 10010, USA; E-Mails: [email protected] (B.L.); [email protected] (F.K.) 3 Department of Neurosurgery, Weill-Cornell Medical College, New York, NY 10065, USA 4 Department of Biological Sciences, Texas Tech University, Lubbock, TX 79409, USA; E-Mail: [email protected] 5 Natural Science Research Laboratory, Museum of Texas Tech University, Lubbock, TX 79409, USA 6 Department of Endocrinology, National University Hospital of Singapore, Singapore 119228; E-Mail: [email protected] 7 Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-646-367-7411 (ext. 123); Fax: +1-212-213-6188. Received: 5 February 2014; in revised form: 26 March 2014 / Accepted: 28 March 2014 / Published: 15 April 2014 Abstract: Chernobyl demonstrated that iodine-131 (131I) released in a nuclear accident can cause malignant thyroid nodules to develop in children within a 300 mile radius of the incident.
    [Show full text]
  • Use of Radioactive Iodine As a Tracer in Water-Flooding Operations
    . USE of RADIOACTIVE IODINE as a TRACER In WATER-FLOODING OPERATIONS Downloaded from http://onepetro.org/jpt/article-pdf/6/09/117/2237549/spe-349-g.pdf by guest on 27 September 2021 J. WADE WATKINS BUREAU OF MINES MEMBER AIME BARTLESVILLE, OKLA. E. S. MARDOCK WELL SURVEYS, INC. MEMBER AIME TULSA, OKLA. T. P. 3894 ABSTRACT assumed that the physical conditions in the productive formation are homogeneous. Unfortunately, homogen­ The accurate evaluation of reservoir-performance eous conditions rarely, if ever, exist in oil-productive characteristics in the secondary recovery of petroleum formations. The use of a tracer that may be injected by water flooding requires use of a water tracer that into an oil sand and detected quantitatively, or even may be injected into water-input wells and detected at qualitatively, at offsetting oil-production wells provides oil-production wells to supplement data obtained fronz basic data that may be used in determining more core analyses, wellhead tests, and subsurface measure­ accurately the subsurface rates and patterns of flow ments. Radioactive iodine has been used successfully of injected water between wells than is possible by as a water tracer in field tests to determine: (1) rela­ theoretical calculations based on assumed conditions. tive rates and patterns of flow of injected water between Consideration of the data obtained by using a water water-input and oil-production wells and (2) zones of tracer assists in the application of remedial measures excessive water entry into oil-production wells. to water-input wells, such as plugging of channels, or Laboratory evaluations of potential water tracers, selective plugging of highly permeable zones, thereby previous tracer studies, the value of using a radioactive effecting a more uniform flood and a greater ultimate tracer, general field procedures, and the use of surface oil recovery.
    [Show full text]
  • Huidige Situatie En Toekomstverkenning
    Stichting Laka: Documentatie- en onderzoekscentrum kernenergie De Laka-bibliotheek The Laka-library Dit is een pdf van één van de publicaties in This is a PDF from one of the publications de bibliotheek van Stichting Laka, het in from the library of the Laka Foundation; the Amsterdam gevestigde documentatie- en Amsterdam-based documentation and onderzoekscentrum kernenergie. research centre on nuclear energy. Laka heeft een bibliotheek met ongeveer The Laka library consists of about 8,000 8000 boeken (waarvan een gedeelte dus ook books (of which a part is available as PDF), als pdf), duizenden kranten- en tijdschriften- thousands of newspaper clippings, hundreds artikelen, honderden tijdschriftentitels, of magazines, posters, video's and other posters, video’s en ander beeldmateriaal. material. Laka digitaliseert (oude) tijdschriften en Laka digitizes books and magazines from the boeken uit de internationale antikernenergie- international movement against nuclear beweging. power. De catalogus van de Laka-bibliotheek staat The catalogue of the Laka-library can be op onze site. De collectie bevat een grote found at our website. The collection also verzameling gedigitaliseerde tijdschriften uit contains a large number of digitized de Nederlandse antikernenergie-beweging en magazines from the Dutch anti-nuclear power een verzameling video's. movement and a video-section. Laka speelt met oa. haar informatie- Laka plays with, amongst others things, its voorziening een belangrijke rol in de information services, an important role in the Nederlandse anti-kernenergiebeweging. Dutch anti-nuclear movement. Appreciate our work? Feel free to make a small donation. Thank you. www.laka.org | [email protected] | Ketelhuisplein 43, 1054 RD Amsterdam | 020-6168294 | L.P.
    [Show full text]
  • Viiith INTERNATIONAL SYMPOSIUM on NUCLEAR MEDICINE
    INIS-mf--10949 VIIIth INTERNATIONAL SYMPOSIUM ON NUCLEAR MEDICINE JUNE 2 - 5, 1986 KARLOVY VARY CZECHOSLOVAKIA ABSTRACTS ABSTRACTS The booklet contains all abstracts of papers submitted in time to the Secretariat of the Symposium. The abstracts were reproduced from the original forms sent by the ithors. The responsibilit >r the contents and gram- matical style the. re lies upon the authors. 17 ANTIBODY GUIDED TUMOR DETECTION IN PATIENTS WITH CARCINOMA. P.Riva.G.Paganelli, C.Cacciaguerra,V.Tison5G.Landi, G. Riceputi,G.Moscatelli.M.Agostini. Istituto Oncologico Romagnolo. Servizio di Medicir.a Nucleare Ospedale M.Bufalini 47023 Cesena ITALY. As a unit of a multicenter clinical trial coordi - nated by the National Reserch Council we studied two groups of patients,in the last three years.In the first group of undred patients affected by ma- lignat melanoma with stage I-IV we were able to de tect the 75% of well documented lesions employing a 99mTC labelled F(ab')2 fragments of MoAb raised a- gainst melanoma (HMW MAA)225.28S(TECNEMAB 1-SORIN BIOMEDICA).In addition a certain number of unknown metastases were also detected and confirmed after- wards. The second group consisted of two-undred pa tients with gastro-intestinal,breast and lung carci^ noma.In these cases we used a 111 In and or 131 I labelled F(ab')i) fragments of a MoAb Raised against CEA(clone F023C5-S'?RIN-Biomedica) with best results in patients bearing colon retto carcinoma and lung cancer.More in detail we obtained the 8<~-% and the 91% of positive scans respectively.In order to im- prove the sensitivity and the tumour/BK ratio some patients with G.I.
    [Show full text]
  • Does Your Patient Have Bile Acid Malabsorption?
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #198 NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #198 Carol Rees Parrish, MS, RDN, Series Editor Does Your Patient Have Bile Acid Malabsorption? John K. DiBaise Bile acid malabsorption is a common but underrecognized cause of chronic watery diarrhea, resulting in an incorrect diagnosis in many patients and interfering and delaying proper treatment. In this review, the synthesis, enterohepatic circulation, and function of bile acids are briefly reviewed followed by a discussion of bile acid malabsorption. Diagnostic and treatment options are also provided. INTRODUCTION n 1967, diarrhea caused by bile acids was We will first describe bile acid synthesis and first recognized and described as cholerhetic enterohepatic circulation, followed by a discussion (‘promoting bile secretion by the liver’) of disorders causing bile acid malabsorption I 1 enteropathy. Despite more than 50 years since (BAM) including their diagnosis and treatment. the initial report, bile acid diarrhea remains an underrecognized and underappreciated cause of Bile Acid Synthesis chronic diarrhea. One report found that only 6% Bile acids are produced in the liver as end products of of British gastroenterologists investigate for bile cholesterol metabolism. Bile acid synthesis occurs acid malabsorption (BAM) as part of the first-line by two pathways: the classical (neutral) pathway testing in patients with chronic diarrhea, while 61% via microsomal cholesterol 7α-hydroxylase consider the diagnosis only in selected patients (CYP7A1), or the alternative (acidic) pathway via or not at all.2 As a consequence, many patients mitochondrial sterol 27-hydroxylase (CYP27A1). are diagnosed with other causes of diarrhea or The classical pathway, which is responsible for are considered to have irritable bowel syndrome 90-95% of bile acid synthesis in humans, begins (IBS) or functional diarrhea by exclusion, thereby with 7α-hydroxylation of cholesterol catalyzed interfering with and delaying proper treatment.
    [Show full text]
  • Multicentre Prospective Survey of Sehcat Provision and Practice in the UK
    BMJ Open Gastroenterol: first published as 10.1136/bmjgast-2016-000091 on 1 May 2016. Downloaded from Imaging Multicentre prospective survey of SeHCAT provision and practice in the UK Jennifer A Summers,1,2 Janet Peacock,1,2 Bolaji Coker,1,2 Viktoria McMillan,3,4 Mercy Ofuya,1,2 Cornelius Lewis,3,4 Stephen Keevil,3,5 Robert Logan,6 John McLaughlin,7,8 Fiona Reid,1,2 To cite: Summers JA, ABSTRACT et al Summary box Peacock J, Coker B, . Objective: A clinical diagnosis of bile acid Multicentre prospective malabsorption (BAM) can be confirmed using SeHCAT survey of SeHCAT provision What is already known about this subject? (tauroselcholic (75selenium) acid), a radiolabelled and practice in the UK. BMJ ▸ Bile acid malabsorption (BAM) is an established Open Gastro 2016;3: synthetic bile acid. However, while BAM can be the cause of chronic diarrhoea and results in signifi- e000091. doi:10.1136/ cause of chronic diarrhoea, it is often overlooked as a cantly adverse quality of life for affected individuals. bmjgast-2016-000091 potential diagnosis. Therefore, we investigated the use ▸ Diagnosis of BAM can be confirmed using of SeHCAT for diagnosis of BAM in UK hospitals. SeHCAT (tauroselcholic (75selenium) acid), a Design: A multicentre survey was conducted radiolabelled synthetic bile acid. However, this capturing centre and patient-level information detailing diagnostic tool is not consistently applied in patient care-pathways, clinical history, SeHCAT results, National Health Service (NHS) centres in the UK. Additional material is treatment with bile acid sequestrants (BAS), and ▸ Patients diagnosed with BAM can benefit from published online only.
    [Show full text]
  • Northern Ireland Nuclear Medicine Equipment Survey, 2017
    Northern Ireland nuclear medicine equipment survey 2017 Northern Ireland nuclear medicine equipment survey 2017 About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support. Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland © Crown copyright 2019 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third-party copyright information you will need to obtain permission from the copyright holders concerned. Published January 2019 PHE publications PHE supports the UN Sustainable Development Goals 2 Northern Ireland nuclear medicine equipment survey 2017 Contents Executive summary 4 Introduction 5 Methodology 6 Number of procedures performed 7 Procedures per scanner 8 Age of Scanners 9 Procedures reported for each organ or system 10 Procedures reported
    [Show full text]
  • Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0*
    Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0* Dominique Delbeke1, R. Edward Coleman2, Milton J. Guiberteau3, Manuel L. Brown4, Henry D. Royal5, Barry A. Siegel5, David W. Townsend6, Lincoln L. Berland7, J. Anthony Parker8, Karl Hubner9, Michael G. Stabin10, George Zubal11, Marc Kachelriess12, Valerie Cronin13, and Scott Holbrook14 1Vanderbilt University Medical Center, Nashville, Tennessee; 2Duke University Medical Center, Durham, North Carolina; 3Christus St. Joseph Hospital, Houston, Texas; 4Henry Ford Hospital, Detroit, Michigan; 5Mallinckrodt Institute of Radiology, St. Louis, Missouri; 6University of Tennessee, Knoxville, Tennessee; 7University of Alabama Hospital, Birmingham, Alabama; 8Beth Israel Deaconess Hospital, Boston, Massachusetts; 9University of Tennessee Medical Center, Knoxville, Tennessee; 10Vanderbilt University, Nashville, Tennessee; 11Yale University, New Haven, Connecticut; 12Institute of Medical Physics, University of Erlangen-Nurnberg, Erlangen, Germany; 13Mercy Hospital, Buffalo, New York; and 14Precision Nuclear, Gray, Tennessee I. PURPOSE available for several years, the readily apparent and doc- umented advantages of having PET and CT in a single device The purpose of these guidelines is to assist physicians in have resulted in the rapid dissemination of this technology recommending, performing, interpreting, and reporting the in the United States. This Procedure Guideline pertains results of 18F-FDG PET/CT for oncologic imaging of adult only to combined PET/CT devices. and pediatric patients. II. BACKGROUND INFORMATION AND DEFINITIONS Definitions PET is a tomographic scintigraphic technique in which a A. A PET/CT scanner is an integrated device containing computer-generated image of local radioactive tracer dis- both a CT scanner and a PET scanner with a single tribution in tissues is produced through the detection of patient table and therefore capable of obtaining a CT annihilation photons that are emitted when radionuclides scan, a PET scan, or both.
    [Show full text]
  • Radionuclides As Tracers
    XA9847600 Chapter 3 RADIONUCLBDES AS TRACERS R.D. Ganatra Nuclear Medicine is usually defined as a "clinical speciality devoted to diagnostic, therapeutic and research applications of internally administered radionuclides.". Diagnostic implies both in vivo and in vitro uses. In modern times, there is hardly any medical research, where a radioactive tracer is not used in some form or other. Normally basic medical research is not considered as nuclear medicine, but clinical research applications of radioisotopes are considered as an integral part of this speciality. Radioisotopes are elements having the same atomic number but different atomic weights. For example, I3II, I25I, 123I are all isotopes of the same element. Their chemical and biological behaviours are expected to be identical. The slight differences in the weights, that they have, is due to differences in the number of particles that they hold inside the nucleus. Some isotopes are perturbed by this kind of change in the nuclear structure. They become unstable, and emit radiation till they reach stable state. These are called radioisotopes. Radioisotopes have few immutable characteristics: they are unstable, they all disintegrate at a specific rate, and they all emit radiations, which have a specific energy pattern. Importance of radioisotopes in medicine is because of their two characteristics: their biological behaviour is identical to their stable counterparts, and because they are radioactive their emissions can be detected by a suitable instrument. All isotopes of iodine will behave in the same way and will concentrate in the thyroid gland. There is no way of detecting the stable, natural iodine in the thyroid gland, but the presence of radioactive iodine can be detected externally in vivo by a detector.
    [Show full text]
  • THE USE of TECHNETIUM 99M AS a CLINICAL TRACER ELEMENT R
    Postgrad Med J: first published as 10.1136/pgmj.41.481.656 on 1 November 1965. Downloaded from POSTGRAD. MED. J. (1965), 41, 656. THE USE OF TECHNETIUM 99m AS A CLINICAL TRACER ELEMENT R. HERBERT, B.Sc., A.Inst.P. W. KULKE, M.B., B.Ch., D.M.R.T., M.Rad. R. T. H. SHEPHERD, B.M., B.Ch., D.M.R.T., F.F.R. The Liverpool Radium Institute, Liverpool, 7. THE VARIETY of radioactive tracer chemicals Production and Physical Properties currently available for medical use is almost Tc99m is most conveniently produced carrier embarrassingly large and is still increasing. free as a pertechnetate (TcO4) in isotonic saline The value of any proposed new isotopes should from a Mo99 generator which has a half-life of therefore be carefully considered. No apology 67 hours. These generators in which the Mo99 however, need be made for the introduction of is incorporated in an alumina column, are Technetium 99m by Scheer and Maier-Borst regularly available from the Radiochemical (1963) also by Harper, Beck, Charleston and Centre, Amersham, England and other suppliers. Lathrop (1964), since this substance has manv Tc99m decays to Tc99 by isomeric transition advantages in its application to scanning and with a half-life of 6.0 hours emitting a 0.140 in the observation of transients. (Clark, Deegan, MeV gamma ray which is 8-11% converted. McKendrick, Herbert and Kulke, 1965). (Strominger, Hollander and Seaborg, 1958). It has been evident for some time that many Tc99 itself decays by beta emission to stable radioisotopes in common use in medicine are Ru99, and has a half-life of 2.1 x 105 years so not best suited for scanning purposes.
    [Show full text]
  • Thermal Properties of 18F-FDG Uptake and Imaging in Positron Emission Tomography Scans of Cancerous Cells
    PANDION: The Osprey Journal of Research & Ideas Volume 2 Number 1 Article 4 2021 Thermal Properties of 18F-FDG Uptake and Imaging in Positron Emission Tomography Scans of Cancerous Cells Carleigh R. Eagle University of North Florida, [email protected] Faculty Mentor: Dr. Jason T. Haraldsen, Associate Professor Department of Physics Follow this and additional works at: https://digitalcommons.unf.edu/pandion_unf Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons, Biological and Chemical Physics Commons, Biomedical Devices and Instrumentation Commons, Medical Biochemistry Commons, Medical Biophysics Commons, Medicinal-Pharmaceutical Chemistry Commons, and the Other Physics Commons Recommended Citation Eagle, Carleigh R. (2021) "Thermal Properties of 18F-FDG Uptake and Imaging in Positron Emission Tomography Scans of Cancerous Cells," PANDION: The Osprey Journal of Research and Ideas: Vol. 2 : No. 1 , Article 4. Available at: https://digitalcommons.unf.edu/pandion_unf/vol2/iss1/4 This Article is brought to you for free and open access by the Student Scholarship at UNF Digital Commons. It has been accepted for inclusion in PANDION: The Osprey Journal of Research & Ideas by an authorized administrator of UNF Digital Commons. For more information, please contact Digital Projects. © 2021 All Rights Reserved Thermal Properties of 18F-FDG Uptake and Imaging in Positron Emission Tomography Scans of Cancerous Cells Cover Page Footnote I would like to thank Dr. Jason T. Haraldsen for all of his help and guidance. Without his support, I would not have the pleasure of publishing in this journal. This article is available in PANDION: The Osprey Journal of Research & Ideas: https://digitalcommons.unf.edu/pandion_unf/vol2/iss1/4 Thermal Properties of 18F-FDG Uptake and Imaging in Positron Emission Tomography Scans of Cancerous Cells Carleigh Rose Eagle Faculty Mentor: Jason T.
    [Show full text]
  • 18F-FDG Labeling of Mesenchymal Stem Cells and Multipotent Adult Progenitor Cells for PET Imaging: Effects on Ultrastructure and Differentiation Capacity
    Journal of Nuclear Medicine, published on January 25, 2013 as doi:10.2967/jnumed.112.108316 18F-FDG Labeling of Mesenchymal Stem Cells and Multipotent Adult Progenitor Cells for PET Imaging: Effects on Ultrastructure and Differentiation Capacity Esther Wolfs1, Tom Struys2,3, Tineke Notelaers4, Scott J. Roberts5, Abhishek Sohni4, Guy Bormans6, Koen Van Laere1, Frank P. Luyten5, Olivier Gheysens1, Ivo Lambrichts2, Catherine M. Verfaillie4, and Christophe M. Deroose1 1Division of Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium; 2Lab of Histology, Department of Functional Morphology, Biomedical Research Institute, Universiteit Hasselt, Diepenbeek, Belgium; 3Biomedical NMR Unit, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium; 4Stem Cell Institute, Department of Development and Regeneration, KU Leuven, Leuven, Belgium; 5Laboratory for Skeletal Development and Joint Disorders, KU Leuven, Leuven, Belgium; and 6Laboratory for Radiopharmacy, KU Leuven, Leuven, Belgium influenced by 18F-FDG labeling. Small-animal PET studies con- Because of their extended differentiation capacity, stem cells firmed the intracellular location of the tracer and the possibility have gained great interest in the field of regenerative medicine. of imaging injected prelabeled stem cell types in vivo. There- For the development of therapeutic strategies, more knowledge fore, direct labeling of MSCs and MAPCs with 18F-FDG is a suit- on the in vivo fate of these cells has to be acquired. Therefore, able technique to noninvasively assess cell delivery and early stem cells can be labeled with radioactive tracer molecules retention with PET. such as 18F-FDG, a positron-emitting glucose analog that is Key Words: mesenchymal stem cell; multipotent adult progenitor taken up and metabolically trapped by the cells.
    [Show full text]